{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:37:53Z","timestamp":1784932673732,"version":"3.55.0"},"reference-count":36,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Poorly differentiated thyroid carcinomas (PDTCs) are rare and aggressive head and neck malignancies with a poor prognosis. Systemic treatment for incurable PDTC consists of multi-kinase inhibitors (MKIs) based on extrapolation from the experience with radioiodine refractory differentiated thyroid cancer (DTC). Cabozantinib is an approved second-line MKI therapy for DTC, but there are limited data regarding the safety and efficacy of cabozantinib for PDTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-institution, retrospective analysis of patients with PDTC who received cabozantinib in any line of therapy. Baseline demographics, disease characteristics, treatment history, toxicity, and clinical outcomes were abstracted from the electronic medical record. Median progression-free survival (PFS) and overall survival (OS) were primary endpoints and estimated using Kaplan\u2013Meier methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven patients with PDTC who received cabozantinib were included. 4\/7 (57%) patients had a partial response to cabozantinib, while 2\/7 (29%) had stable disease (SD) as their best response. The median time on treatment for cabozantinib was 10.53 months. The median PFS from the start of cabozantinib was 12.9 months, and median OS was 14.21 months. Most adverse events to treatment (5\/6) were low grade. Two (29%) patients were alive at the date of the last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cabozantinib is an effective and reasonably well-tolerated treatment option for patients with PDTC. Prospective studies are needed to further investigate the role of cabozantinib in the treatment of PDTC, alone and in combination with other agents, including checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0225","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:56:09Z","timestamp":1730465769000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":6,"title":["Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma"],"prefix":"10.1530","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-8035","authenticated-orcid":true,"given":"Omar","family":"Elghawy","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-7530","authenticated-orcid":true,"given":"Adam","family":"Barsouk","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-2964","authenticated-orcid":true,"given":"Lova","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Thyroid","first-page":"311","article-title":"Poorly differentiated carcinoma of the thyroid gland: current status and future prospects","volume":"29","author":"Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic TGhossein RShah JP & Ganly I. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 2019 29 311\u2013321. (https:\/\/doi.org\/10.1089\/thy.2018.0509)"},{"key":"bib2","series-title":"Anticancer Research","first-page":"2531","article-title":"Poorly differentiated thyroid carcinoma: single institution series of outcomes","volume":"42","author":"Kunte","year":"2022","unstructured":"Kunte SSharett JWei WNasr CPrendes BLamarre EKu JLorenz RRScharpf JBurkey BB, et al. Poorly differentiated thyroid carcinoma: single institution series of outcomes. Anticancer Research 2022 42 2531\u20132539. (https:\/\/doi.org\/10.21873\/anticanres.15731)"},{"key":"bib3","series-title":"European Thyroid Journal","first-page":"e230003","article-title":"Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma","volume":"12","author":"Roque","year":"2023","unstructured":"Roque JNunes Silva TRegala CRodrigues R & Leite V. Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma. European Thyroid Journal 2023 12 e230003. (https:\/\/doi.org\/10.1530\/ETJ-23-0003)"},{"key":"bib4","series-title":"Journal of Personalized Medicine","first-page":"654","article-title":"The long journey towards personalized targeted therapy in poorly differentiated thyroid carcinoma (PDTC): a case report and systematic review","volume":"14","author":"Violetis","year":"2024","unstructured":"Violetis OKonstantakou PSpyroglou AXydakis AKekis PBTseleni SKolomodi DKonstadoulakis MMastorakos GTheochari M, et al. The long journey towards personalized targeted therapy in poorly differentiated thyroid carcinoma (PDTC): a case report and systematic review. Journal of Personalized Medicine 2024 14 654. (https:\/\/doi.org\/10.3390\/jpm14060654)"},{"key":"bib5","series-title":"European Thyroid Journal","first-page":"e220021","article-title":"Poorly differentiated thyroid carcinoma: a clinician\u2019s perspective","volume":"11","author":"Tong","year":"2022","unstructured":"Tong JRuan MJin YFu HCheng LLuo QLiu ZLv Z & Chen L. Poorly differentiated thyroid carcinoma: a clinician\u2019s perspective. European Thyroid Journal 2022 11 e220021. (https:\/\/doi.org\/10.1530\/ETJ-22-0021)"},{"key":"bib6","series-title":"Langenbeck\u2019s Archives of Surgery","first-page":"45","article-title":"Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference?","volume":"404","author":"Bichoo","year":"2019","unstructured":"Bichoo RAMishra AKumari NKrishnani NChand GAgarwal GAgarwal A & Mishra SK. Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference? Langenbeck\u2019s Archives of Surgery 2019 404 45\u201353. (https:\/\/doi.org\/10.1007\/s00423-019-01753-6)"},{"key":"bib7","series-title":"American Journal of Surgical Pathology","first-page":"1866","article-title":"Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed?","volume":"35","author":"Dettmer","year":"2011","unstructured":"Dettmer MSchmitt ASteinert HHaldemann AMeili AMoch HKomminoth P & Perren A. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? American Journal of Surgical Pathology 2011 35 1866\u20131872. (https:\/\/doi.org\/10.1097\/PAS.0b013e31822cf962)"},{"key":"bib8","series-title":"Journal of the National Comprehensive Cancer Network","first-page":"925","article-title":"Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","unstructured":"Haddad RIBischoff LBall DBernet VBlomain EBusaidy NLCampbell MDickson PDuh QYEhya H, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2022 20 925\u2013951. (https:\/\/doi.org\/10.6004\/jnccn.2022.0040)"},{"key":"bib9","series-title":"Cancers","first-page":"5309","article-title":"Course of disease and clinical management of patients with poorly differentiated thyroid carcinoma","volume":"13","author":"Grawe","year":"2021","unstructured":"Grawe FCahya AFabritius MPBeyer LWenter VRuebenthaler JGeyer TBurgard CBartenstein PIlhan H, et al. Course of disease and clinical management of patients with poorly differentiated thyroid carcinoma. Cancers 2021 13 5309. (https:\/\/doi.org\/10.3390\/cancers13215309)"},{"key":"bib10","series-title":"Cancer Management and Research","first-page":"3047","article-title":"Management of progressive radioiodine-refractory thyroid carcinoma: current perspective","volume":"14","author":"Nervo","year":"2022","unstructured":"Nervo ARetta FRagni APiovesan AGallo M & Arvat E. Management of progressive radioiodine-refractory thyroid carcinoma: current perspective. Cancer Management and Research 2022 14 3047\u20133062. (https:\/\/doi.org\/10.2147\/CMAR.S340967)"},{"key":"bib11","series-title":"Lancet","first-page":"319","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","unstructured":"Brose MSNutting CMJarzab BElisei RSiena SBastholt Lde la Fouchardiere CPacini FPaschke RShong YK, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014 384 319\u2013328. (https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9)"},{"key":"bib12","series-title":"New England Journal of Medicine","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","unstructured":"Schlumberger MTahara MWirth LJRobinson BBrose MSElisei RHabra MANewbold KShah MHHoff AO, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine 2015 372 621\u2013630. (https:\/\/doi.org\/10.1056\/NEJMoa1406470)"},{"key":"bib13","series-title":"Endocrine","first-page":"462","article-title":"Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival","volume":"72","author":"De Leo","year":"2021","unstructured":"De Leo SDi Stefano MPersani LFugazzola L & Colombo C. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine 2021 72 462\u2013469. (https:\/\/doi.org\/10.1007\/s12020-020-02477-0)"},{"key":"bib14","series-title":"Thyroid","first-page":"72","article-title":"Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice","volume":"28","author":"Berdelou","year":"2018","unstructured":"Berdelou ABorget IGodbert YNguyen TGarcia MEChougnet CNFerru ABuffet CChabre OHuillard O, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 2018 28 72\u201378. (https:\/\/doi.org\/10.1089\/thy.2017.0205)"},{"key":"bib15","series-title":"Journal of the Endocrine Society","first-page":"bvac048","article-title":"Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects","volume":"6","author":"Hamidi","year":"2022","unstructured":"Hamidi SBoucher ALemieux BRondeau GLeboef RSte-Marie LGLe XK & Mircescu H. Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects. Journal of the Endocrine Society 2022 6 bvac048. (https:\/\/doi.org\/10.1210\/jendso\/bvac048)"},{"key":"bib16","series-title":"Advances in Therapy","first-page":"3850","article-title":"Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan","volume":"37","author":"Takahashi","year":"2020","unstructured":"Takahashi STahara MIto KTori MKiyota NYoshida KSakta Y & Yoshida A. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Advances in Therapy 2020 37 3850\u20133862. (https:\/\/doi.org\/10.1007\/s12325-020-01433-8)"},{"key":"bib17","series-title":"Endocrine","first-page":"142","article-title":"Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina","volume":"69","author":"Jerkovich","year":"2020","unstructured":"Jerkovich FCalifano IBueno FCarrera JMGiglio RAbelleira E & Pitoia F. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine 2020 69 142\u2013148. (https:\/\/doi.org\/10.1007\/s12020-020-02290-9)"},{"key":"bib18","series-title":"Thyroid","first-page":"91","article-title":"Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study","volume":"33","author":"Kim","year":"2023","unstructured":"Kim MJin MJeon MJKim EYShin DYLim DJKim BHKang HCKim WBShong YK, et al. Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid 2023 33 91\u201399. (https:\/\/doi.org\/10.1089\/thy.2022.0054)"},{"key":"bib19","series-title":"Thyroid","first-page":"732","article-title":"Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea","volume":"30","author":"Song","year":"2020","unstructured":"Song EKim MKim EYKim BHShin DYKang HCAhn BCKim WBShong YKJeon MJ, et al. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 2020 30 732\u2013738. (https:\/\/doi.org\/10.1089\/thy.2019.0476)"},{"key":"bib20","series-title":"Lancet Oncology","first-page":"1126","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","unstructured":"Brose MSRobinson BSherman SIKrajewska JLin CCVaisman FHoff AOHitre EBowles DWHernando J, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2021 22 1126\u20131138. (https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6)"},{"key":"bib21","series-title":"Journal of Clinical Oncology","first-page":"3315","article-title":"Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter Phase II international thyroid oncology group trial","volume":"35","author":"Cabanillas","year":"2017","unstructured":"Cabanillas MEde Souza JAGeyer SWirth LJMenefee MELiu SVShah KWright J & Shah MH. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter Phase II international thyroid oncology group trial. Journal of Clinical Oncology 2017 35 3315\u20133321. (https:\/\/doi.org\/10.1200\/JCO.2017.73.0226)"},{"key":"bib22","series-title":"Modern Pathology","first-page":"1269","article-title":"Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression","volume":"23","author":"Asioli","year":"2010","unstructured":"Asioli SErickson LARighi AJin LVolante MJenkins SPapotti MBussolati G & Lloyd RV. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern Pathology 2010 23 1269\u20131278. (https:\/\/doi.org\/10.1038\/modpathol.2010.117)"},{"key":"bib23","series-title":"CA: A Cancer Journal for Clinicians","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","unstructured":"Amin MBGreene FLEdge SBCompton CCGershenwald JEBrookland RKMeyer LGress DMByrd DR & Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA: A Cancer Journal for Clinicians 2017 67 93\u201399. (https:\/\/doi.org\/10.3322\/caac.21388)"},{"key":"bib24","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm..Accessed on 5 June 2024."},{"key":"bib25","series-title":"Frontiers in Endocrinology","first-page":"920857","article-title":"Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis","volume":"13","author":"Huang","year":"2022","unstructured":"Huang DZhang JZheng X & Gao M. Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis. Frontiers in Endocrinology 2022 13 920857. (https:\/\/doi.org\/10.3389\/fendo.2022.920857)"},{"key":"bib26","series-title":"Thyroid","first-page":"657","article-title":"Clinical application of next-generation sequencing in advanced thyroid cancers","volume":"32","author":"Ma","year":"2022","unstructured":"Ma LXEspin-Garcia OBedard PLStockley TPrince RMete O & Krzyzanowska MK. Clinical application of next-generation sequencing in advanced thyroid cancers. Thyroid 2022 32 657\u2013666. (https:\/\/doi.org\/10.1089\/thy.2021.0542)"},{"key":"bib27","series-title":"Endocrine Connections","first-page":"47","article-title":"Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer","volume":"7","author":"Gerber","year":"2018","unstructured":"Gerber TSSchad AHartmann NSpringer EZechner U & Musholt TJ. Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer. Endocrine Connections 2018 7 47\u201355. (https:\/\/doi.org\/10.1530\/EC-17-0290)"},{"key":"bib28","series-title":"Journal of Clinical Oncology","first-page":"2359","article-title":"Open-label, single-arm, multicenter, Phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","unstructured":"Wirth LJBrose MSSherman EJLicitra LSchlumberger MSherman SIBible KCRobinson BRodien PGodbert Y, et al. Open-label, single-arm, multicenter, Phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. Journal of Clinical Oncology 2021 39 2359\u20132366. (https:\/\/doi.org\/10.1200\/JCO.20.03093)"},{"key":"bib29","series-title":"Cancer","first-page":"4203","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","unstructured":"Brose MSRobinson BGSherman SIJarzab BLin CCVaisman FHoff AOHitre EBowles DWSen S, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer 2022 128 4203\u20134212. (https:\/\/doi.org\/10.1002\/cncr.34493)"},{"key":"bib30","series-title":"Annals of Oncology","first-page":"2813","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","unstructured":"Schlumberger MElisei RM\u00fcller SSch\u00f6ffski PBrose MShah MLicitra LKrajewska JKreissl MCNiederle B, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Annals of Oncology 2017 28 2813\u20132819. (https:\/\/doi.org\/10.1093\/annonc\/mdx479)"},{"key":"bib31","series-title":"Clinical Cancer Research","first-page":"4173","article-title":"FDA approval summary: cabozantinib for differentiated thyroid cancer","volume":"28","author":"Duke","year":"2022","unstructured":"Duke ESBarone AKChatterjee SMishra-Kalyani PSShen YLIsikwei EZhao HBi YLiu JRahman NA, et al. FDA approval summary: cabozantinib for differentiated thyroid cancer. Clinical Cancer Research 2022 28 4173\u20134177. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0873)"},{"key":"bib32","series-title":"Thyroid","first-page":"1508","article-title":"A Phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer","volume":"24","author":"Cabanillas","year":"2014","unstructured":"Cabanillas MEBrose MSHolland JFerguson KC & Sherman SI. A Phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 2014 24 1508\u20131514. (https:\/\/doi.org\/10.1089\/thy.2014.0125)"},{"key":"bib33","series-title":"Thyroid","first-page":"1076","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","unstructured":"Dierks CSeufert JAumann KRuf JKlein CKiefer SRassner MBoerries MZielke Ala Rosee P, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 2021 31 1076\u20131085. (https:\/\/doi.org\/10.1089\/thy.2020.0322)"},{"key":"bib34","article-title":"Study Details | Nivolumab Plus Ipilimumab in Thyroid Cancer | ClinicalTrials.gov","unstructured":"Study Details | Nivolumab Plus Ipilimumab in Thyroid Cancer | ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03246958..Accessed on 9 July 2024."},{"key":"bib35","series-title":"Annals of Oncology","first-page":"S498","article-title":"723O cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: a multi-cohort basket phase II trial (CABATEN\/GETNE-T1914)","volume":"34","author":"Castillon","year":"2023","unstructured":"Castillon JCMolina-Cerrillo JVi\u00f1uales MBGarcia-Carbonero RTeule ACustodio AJimenez-Fonseca PL\u00f3pez CHierro CCarmona-Bayonas A, et al. 723O cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: a multi-cohort basket phase II trial (CABATEN\/GETNE-T1914). Annals of Oncology 2023 34 S498. (https:\/\/doi.org\/10.1016\/j.annonc.2023.09.670)"},{"key":"bib36","series-title":"Maedica","first-page":"221","article-title":"Overall survival of patients with aggressive thyroid cancer on fine-needle aspiration biopsy examination. A tertiary Romanian center experience","volume":"10","author":"Mogos","year":"2015","unstructured":"Mogos ICNiculescu DAIoachim DIorgulescu R & Poiana C. Overall survival of patients with aggressive thyroid cancer on fine-needle aspiration biopsy examination. A tertiary Romanian center experience. Maedica 2015 10 221\u2013225."}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/13\/6\/ETJ-24-0225.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/6\/ETJ-24-0225.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/6\/ETJ-24-0225.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:52:06Z","timestamp":1784555526000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/4355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":36,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0225","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}